

May 30, 2023

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub: Disclosure of Related Party Transactions under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFO/CMD1/CIR/P/2021/662 dated November 22, 2021, please find enclosed disclosure of related party transactions for half year ended March 31, 2023.

This is for your kind information and record please.

Thanking you,

Sincerely yours,
For **Panacea Biotec Ltd.**

Devender Gupta
Chief Financial Officer and
Head Information Technology

Encls: As Above

Related Party Transaction for half year ended March 31, 2023

(Rs. in million)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken																					
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Natureof indebtedness (loan / issuances of debt / any other etc.)	Detail of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
1	Panacea Biotec Ltd.		Adveta Power Pvt Ltd.		Joint Venture	Any other transaction	Rental Income		As approved by audit committee and Board	0.08	0.34	0.43									
2	Panacea Biotec Ltd.		Adveta Power Pvt Ltd.		Joint Venture	Investment			As approved by audit committee and Board	-	0.90	0.90									
3	Panacea Biotec Pharma Ltd.		Adveta Power Pvt Ltd.		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Interest received			As approved by audit committee and Board	0.01	-	-									
4	Panacea Biotec Pharma Ltd.		Adveta Power Pvt Ltd.		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Loan			As approved by audit committee and Board	0.20	-	0.20					Inter-Corporate	9%	2 years	Unsecured	For working capital requirements
5	Panacea Biotec Pharma Ltd.		Adveta Power Pvt Ltd.		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Any other transaction	Interest accrued		As approved by audit committee and Board	0.01	-	-									
6	Panacea Biotec Ltd.		Ankesh Jain		Whole - time Director	Remuneration			As approved by audit committee and Board	1.54	-	-									
7	Panacea Biotec Ltd.		Ashwani Jain		Chief Operating Officer	Remuneration			As approved by audit committee and Board	1.48	-	-									
8	Panacea Biotec Ltd.		Bhupinder Singh		Independent Director	Remuneration			As approved by audit committee and Board	0.10	-	-									
9	Panacea Biotec Ltd.		Devender Gupta		CFO and Head IT	Remuneration			As approved by audit committee and Board	2.79	-	-									
10	Panacea Biotec Ltd.		Dr. Rajesh Jain		Chairman & Managing Director	Interest paid			As approved by audit committee and Board	6.77	153.16	150.00									
11	Panacea Biotec Ltd.		Dr. Rajesh Jain		Chairman & Managing Director	Remuneration			As approved by audit committee and Board	4.35	-	-									

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken																					
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Natureof indebtedness (loan / issuances of debt / any other etc.)	Detail of other indebt dness	Cost	Tenur e	Nature (loan/ advance/ inter-corporate deposit/ investment	Interes t Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
12	Panacea Biotec Ltd.		Harshet Jain		Member of Promoter Group	Remuneration			As approved by audit committee and Board	0.55	-	-									
13	Panacea Biotec Ltd.		K. M. Lal		Independent Director	Remuneration			As approved by audit committee and Board	0.14	-	-									
14	Panacea Biotec Pharma Ltd.		Manjula Upadhyay		Independent Director	Remuneration			As approved by audit committee and Board	0.12	-	-									
15	Panacea Biotec Ltd.		Manjula Upadhyay		Independent Director	Remuneration			As approved by audit committee and Board	0.10	-	-									
16	Panacea Biotec Ltd.		Meyten Realtech Pvt.Ltd		Subsidiary	Any other transaction	Rental Income		As approved by audit committee and Board	0.01	0.13	0.14									
17	Panacea Biotec Ltd.		Meyten Realtech Pvt.Ltd		Subsidiary	Interest received			As approved by audit committee and Board	0.10	0.16	0.24									
18	Panacea Biotec Ltd.		Meyten Realtech Pvt.Ltd		Subsidiary	Any other transaction	Rent Paid		As approved by audit committee and Board	5.17	18.97	21.92									
19	Panacea Biotec Ltd.		Meyten Realtech Pvt.Ltd		Subsidiary	Loan			As approved by audit committee and Board		2.30	2.30									
20	Panacea Biotec Ltd.		Meyten Realtech Pvt.Ltd		Subsidiary	Investments			As approved by audit committee and Board	-	0.10	0.10									
21	Panacea Biotec Ltd.		MR Lex Corp LLP		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Purchase of goods or services			As approved by audit committee and Board	1.32	0.57	1.25									
22	Panacea Biotec Ltd.		Mukul Gupta		Independent Director	Remuneration			As approved by Audit Committee and Board	0.10	-	-									
23	Panacea Biotec Ltd.		N. N. Khamitkar		Independent Director	Remuneration			As approved by Audit Committee and Board	0.13	-	-									
24	Panacea Biotec Ltd.		Narotam Kumar Juneja		Non-Executive Director	Remuneration			As approved by Audit Committee and Board	0.10	-	-									

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken																						
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan / issuances of debt / any other etc.)	Detail of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)	
25	Panacea Biotec Ltd.		Neophar Alipro Ltd.		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Any other transaction	Rental Income		As approved by audit committee and Board	0.09	-	-										
26	Panacea Biotec Ltd.		Nirmala Jain		Member of Promoter Group	Interest paid			As approved by audit committee and Board	6.66	-	-										
27	Panacea Biotec Ltd.		Panacea Biotec (International) S.A., Switzerland		Subsidiary	Any other transaction	Allowance for doubtful loan		As approved by audit committee and Board		96.79	96.79										
28	Panacea Biotec Ltd.		Panacea Biotec (International) S.A., Switzerland		Subsidiary	Loan			As approved by audit committee and Board		96.79	96.79										
29	Panacea Biotec Ltd.		Panacea Biotec (International) S.A., Switzerland		Subsidiary	Investments			As approved by audit committee and Board	-	34.36	34.36										
30	Panacea Biotec Ltd.		Panacea Biotec (International) S.A., Switzerland		Subsidiary	Any other transaction	Provision for impairment of Investment		As approved by audit committee and Board	-	34.36	34.36										
31	Panacea Biotec Ltd.		Panacea Biotec Germany Gmbh		Indirectly wholly owned subsidiary	Any other transaction	Allowance for doubtful loan		As approved by audit committee and Board		319.42	319.42										
32	Panacea Biotec Ltd.		Panacea Biotec Germany Gmbh		Indirectly wholly owned subsidiary	Loan			As approved by audit committee and Board		319.42	319.42										
33	Panacea Biotec Ltd.		Panacea Biotec Germany Gmbh		Indirectly wholly owned subsidiary	Any other transaction	Trade Receivable		As approved by audit committee and Board	0.11	1.00	1.11										
34	Panacea Biotec Ltd.		Panacea Biotec Germany Gmbh		Indirectly wholly owned subsidiary	Any other transaction	Trade payable		As approved by audit committee and Board	2.17	18.84	21.02										
35	Panacea Biotec Pharma Ltd.		Panacea Biotec Germany Gmbh		Indirectly wholly owned subsidiary of Holding Company	Any other transaction	Trade Receivable		As approved by audit committee and Board	45.74	-	1.95										
36	Panacea Biotec Ltd.		Panacea Biotec Pharma Ltd.		Subsidiary	Sale of goods or services			As approved by audit committee and Board	0.57	-	-										
37	Panacea Biotec Ltd.		Panacea Biotec Pharma Ltd.		Subsidiary	Any other transaction	Rental Income		As approved by audit committee and Board	11.50	-	-										
38	Panacea Biotec Ltd.		Panacea Biotec Pharma Ltd.		Subsidiary	Any other transaction	Interest accrued on loan received		As approved by audit committee and Board	35.37	22.32	54.15										
39	Panacea Biotec Ltd.		Panacea Biotec Pharma Ltd.		Subsidiary	Purchase of goods or services			As approved by audit committee and Board	7.86	177.35	177.15										

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken																					
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Natureof indebtedness (loan / issuances of debt / any other etc.)	Detail of other indebt dness	Cost	Tenur e	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interes t Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
55	Panacea Biotec Ltd.		Ravinder Heights Limited		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Any other transaction	Trade Receivable		As approved by audit committee and Board	-	0.76	0.76									
56	Panacea Biotec Ltd.		Sandeep Jain		Joint Managing Director	Remuneration			As approved by Nomination and remuneration Committee, Audit Committee and Board	3.96	-	-									
57	Panacea Biotec Ltd.		Soshil Kumar Jain		Former Chairman	Remuneration			As approved by Nomination and remuneration Committee, Audit Committee and Board	30.61		-									
58	Panacea Biotec Ltd.		Soshil Kumar Jain		Former Chairman	Interest paid			As approved by audit committee and Board	7.05	27.51	-									
59	Panacea Biotec Ltd.		Tanish Jain		Relative of Promoter	Remuneration			As approved by Nomination and remuneration Committee, Audit Committee and Board	0.30	-	-									
60	Panacea Biotec Ltd.		Trinidhi Finance Pvt. Ltd.		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Any other transaction	Trade Receivable		As approved by audit committee and Board	-	0.10	0.10									
61	Panacea Biotec Ltd.		Vinod Goel		Group CFO and Head Legal & CS	Remuneration			As approved by Nomination and remuneration Committee, Audit Committee and Board	3.39	-	-									
62	Panacea Biotec Ltd.		Vinod Goel		Group CFO and Head Legal & CS	Any other transaction	Advance against salary		As approved by audit committee and Board	0.24	1.30	1.06									